Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Dividends

Xenia Hotels & Resorts: A Story of Contrasts in the Hospitality Sector

Robert Sasse by Robert Sasse
November 1, 2025
in Dividends, Earnings, Real Estate & REITs, Turnaround
0
Xenia Hotels, Resorts Stock
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

Xenia Hotels & Resorts presents a complex financial narrative, marked by a significant third-quarter net loss of $13.7 million. Despite this setback, the real estate investment trust (REIT) demonstrated underlying resilience through steady revenue and a solid dividend distribution, showcasing its strategic navigation of the volatile hotel industry.

Financial Performance: Losses and Underlying Strength

The company reported a net loss of $0.14 per share. However, a more encouraging metric, the adjusted funds from operations (FFO), came in at $0.23 per share. Although this figure represents an 8% decrease compared to the same period last year, it points to the firm’s fundamental operational health. Revenue remained stable at $236.4 million, a notable achievement given current market conditions.

Key operational data reveals a mixed picture. The Revenue Per Available Room (RevPAR) held steady at $164.50, while the occupancy rate declined by 100 basis points to 66.3%. A positive note was the 1.6% increase in the average daily rate, which rose to $248.09.

  • Adjusted EBITDAre: $42.2 million (a 4.6% decrease versus Q3 2024)
  • Total RevPAR: Increased by 3.7% to $289.76
  • Share Repurchases: 974,645 shares bought back at an average price of $12.66 per share
  • Dividend: A payment of $0.14 per share was distributed

Divergent Regional Results and Group Business Momentum

A deep dive into regional performance reveals extreme variations. Phoenix experienced an explosive RevPAR growth of 123.2%, largely driven by the completed renovations at the Grand Hyatt Scottsdale, highlighting the latent potential within Xenia’s property portfolio. In stark contrast, the Houston market struggled with a 21.2% plunge in RevPAR.

Should investors sell immediately? Or is it worth buying Xenia Hotels, Resorts?

The potential game-changer for Xenia, however, appears to be its group business segment. While the leisure travel market shows signs of softening, the company is demonstrating strength in the more lucrative corporate client sector, with confirmed room revenue already on the books for 2026.

Strategic Capital Allocation and Future Outlook

Xenia continues to prioritize growth through strategic investments, with $90 million in planned capital expenditures. A significant portion of this, $9 million, is allocated to the W Nashville project. Upon stabilization, this investment is projected to generate an incremental $3 to $5 million in Hotel EBITDA.

Looking ahead, management’s full-year 2025 guidance projects an adjusted EBITDAre of $254 million and an FFO per share of $1.72. The forecast of a 4% increase in RevPAR indicates a measured sense of optimism.

The question remains: can Xenia orchestrate a full turnaround? The company’s strategy—combining targeted investments, a robust group booking pipeline, and disciplined capital allocation—suggests a positive trajectory. Nevertheless, persistent margin pressures and significant regional volatility remain critical challenges on the path to a sustainably profitable future.

Ad

Xenia Hotels, Resorts Stock: Buy or Sell?! New Xenia Hotels, Resorts Analysis from February 7 delivers the answer:

The latest Xenia Hotels, Resorts figures speak for themselves: Urgent action needed for Xenia Hotels, Resorts investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Xenia Hotels, Resorts: Buy or sell? Read more here...

Tags: Xenia Hotels, Resorts
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Conduent Stock

Conduent Shares Decline Amid Board Reshuffle and Data Breach Fallout

Forum Energy Technologies Stock

Forum Energy Technologies Posts Impressive Third Quarter Results

Gannett Stock

Gannett's Pivotal Quarter: Balancing Debt Reduction and Digital Transformation

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com